News & Resources

Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory

August 15, 2022 Press Releases

Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy

August 15, 2022 Press Releases

This Startup is Creating a Toothpaste for Your Peanut Allergy

August 15, 2022 In the News

INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose

April 4, 2022 Press Releases

Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy

February 8, 2022 Press Releases

Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

December 21, 2021 Press Releases

Unicorn Hunters

Corporate Deck

White Paper

Request your copy of our white paper

Videos

Want to learn more about Intrommune and our OMIT technology? Watch the videos below.

The time is now for a desensitization method that is safe, effective and easy to use. This is exactly the solution that Intrommune Therapeutics offers.

Tonya Winders

President, CEO
Allergy & Asthma Network